TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
EQL Pharma AB ( (SE:EQL) ) has shared an update.
EQL Pharma AB has applied for its senior secured bonds, initially issued in January 2025, to be traded on the corporate bond list of Nasdaq Stockholm, moving from the Nasdaq First North Bond Market. This transition, expected to occur around 19 November 2025, is accompanied by the publication of a prospectus approved by the Swedish Financial Supervisory Authority, marking a significant step in the company’s financial strategy.
More about EQL Pharma AB
EQL Pharma AB specializes in developing and selling generic drugs that are medically equivalent to original drugs, focusing on niche generics with limited competition. The company operates primarily in the Nordic and European markets, concentrating on prescription drugs, including hospital products. EQL Pharma is based in Lund and is listed on the Nasdaq Stockholm stock market, collaborating with leading contract manufacturers and pharmaceutical companies in the EU and Asia.
YTD Price Performance: -33.09%
Average Trading Volume: 51,797
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.6B
See more insights into EQL stock on TipRanks’ Stock Analysis page.